Ads
related to: sickle cell trait- Mechanism Of Action
Learn About The LYFGENIA
MOA & How It Works.
- Treatment Pathway
Get An Overview Of The Treatment
Steps With LYFGENIA.
- Request A Representative
Fill Out The Online Form To Be
Contacted About LYFGENIA.
- FAQs
Get Answers To Questions
About Treatment With LYFGENIA.
- Mechanism Of Action
Search results
Results From The WOW.Com Content Network
Hemoglobin A2 (HbA 2) is a normal variant of hemoglobin A that consists of two alpha and two delta chains (α 2 δ 2) and is found at low levels in normal human blood.Hemoglobin A2 may be increased in beta thalassemia or in people who are heterozygous for the beta thalassemia gene.
Delta-beta thalassemia can mask the diagnosis of beta thalassemia trait. In beta thalassemia, an increase in hemoglobin A2 results, but the co-existence of a delta-beta thalassemia mutation will decrease the value of the hemoglobin A2 into the normal range, thereby obscuring the diagnosis of beta thalassemia trait [10]
In persons with sickle cell disease, high levels of fetal hemoglobin as found in a newborn or as found abnormally in persons with hereditary persistence of fetal hemoglobin, the HbF causes the sickle cell disease to be less severe. In essence the HbF inhibits polymerization of HbS. A similar mechanism occurs with persons who have sickle cell trait.
The acute chest syndrome is a vaso-occlusive crisis of the pulmonary vasculature commonly seen in people with sickle cell anemia. This condition commonly manifests with a new opacification of the lung(s) on a chest x-ray .
Proliferative sickle retinopathy is the most severe ocular complication of sickle cell disease. Even though PSCR begins in the first decade of life, the condition remains asymptomatic and unnoticed until visual symptoms occur due to vitreous hemorrhage or retinal detachment.
Gene editing therapies aimed at increasing fetal hemoglobin production in beta thalassemia as well as sickle cell anemia by inhibiting the BCL11A gene have been developed. [ 44 ] [ 45 ] Exagamglogene autotemcel , sold under the brand name Casgevy, is a gene therapy for the treatment of transfusion-dependent beta thalassemia developed by Vertex ...
The most frequent cause of autosplenectomy is sickle cell anemia [10] which causes progressive splenic hypofunction over time. Increased deoxygenation causes sickling of red blood cells, which adhere to the spleen wall and splenic macrophages causing ischemia. [2]
Hakulinen E (March 1990). "The man behind the syndrome. James B Herrick: the discoverer of sickle cell anemia. His first case report received scant interest--only in the 1950s was the role of "moon-crescent" shape considered" [The man behind the syndrome. James B Herrick: the discoverer of sickle cell anemia.